• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Add-On Buprenorphine for Methamphetamine Use Disorder

Add-On Buprenorphine for Methamphetamine Use Disorder

March 1, 2022
Sanya Virani, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Sanya Virani, MD. Dr. Virani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Kheirabadi GR et al, J Clin Psychopharmacol 2021;41(1):45–48

STUDY TYPE: Randomized controlled trial

Methamphetamine (meth) addiction is notoriously difficult to treat. There are no FDA-approved medications, and even the most promising trials have mixed results. People withdrawing from meth experience dysphoria, anxiety, mood instability, sleep disturbances, and intense drug cravings. In this study, researchers chose to investigate whether treating drug cravings could decrease participants’ meth use, and secondarily, whether this would lead to improvements in the depression, stress, and anxiety experienced during withdrawal. Targeting cravings seems intuitive, but the researchers made the unusual decision to use buprenorphine (bup), the mu-opioid partial agonist, as their anti-craving agent.

Bup is best known as a treatment for opioid use disorder (OUD), but it is hypothesized to have the potential for more general anti-craving effects by inducing dopamine release from the nucleus accumbens. While we don’t have any convincing human data yet, animal studies have shown that bup alters the dopamine neurotransmission brought about by meth that is thought to correlate with drug craving (Pereira FC et al, Neurotox Res 2011;19(1):94–101). The researchers in this study therefore theorized that bup’s potential anti-craving effect might be applicable to patients addicted to meth.

The researchers conducted a randomized, double-blind, placebo-controlled trial of 40 participants (30 men and 10 women), with an average age of 32.3 years and an average meth-addiction duration of 2.49 years. Half were assigned to receive bup (2 mg daily for one week, 4 mg daily for six weeks, then 2 mg for one week) while half received placebo. All participants enrolled in the same 16-week intensive multimodal psychotherapy program.

Over the study’s 24 weeks, those taking bup did better on all outcomes. Drug cravings were measured weekly for the first eight weeks and monthly thereafter, and the intervention group had modestly but significantly lower drug cravings at all time points after the first two weeks. Consistent with the hypothesis that treating cravings might improve sobriety, the intervention group had fewer meth-positive urine tests, with a mean of 5.80 positives in the bup group versus 7.80 in the placebo group (p < 0.001). Secondary endpoints of depression, anxiety, and stress were also slightly better in the treatment group versus the placebo group, at least at the two-month time point, which was the only time point reported in the study.

The small number of trial participants is a limitation, but not unusual for a study of this nature. However, several other key questions are left unanswered. Whether participants had a period of sobriety at the time of enrolling in the trial was not addressed. Neither was the authors’ choice to use unusually tiny doses of bup. And while outcomes reached statistical significance, the clinical utility of this approach remains questionable.

CATR’s Take
Bup did reduce cravings and abstinence in people with meth addiction in this small study, but lots of question marks remain about prescribing an unusual dose of a controlled substance for a non-FDA-approved indication. This approach is promising, so keep an eye out for future developments, but prescribing bup for meth addiction should remain in the realm of research until we have better clinical data. In the meantime, see the May/June 2021 CATR for a Q&A and clinical update on treating stimulant use disorders.
Addiction Treatment
KEYWORDS buprenorphine methamphetamines stimulant-use-disorder
    Sanya Virani, MD.

    Antipsychotics for Methamphetamine Psychosis

    More from this author
    www.thecarlatreport.com
    Issue Date: March 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Real-World Alcohol Use Disorder Treatment
    Alcohol-Induced Liver Disease
    Medications for Alcohol Use Disorder: An Overview
    Add-On Buprenorphine for Methamphetamine Use Disorder
    Unintended Pregnancies in Opioid Use Disorder
    CME Post-Test - Alcohol Use Disorder, CATR, March/April 2022
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.